

08-15-05

1fw

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/828,669-Conf. #6169
	Filing Date	April 21, 2004
	First Named Inventor	Michael D. Schneider
	Art Unit	1645
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	HO-P02767US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	FULBRIGHT & JAWORSKI L.L.P.		
Signature			
Printed name	Melissa W. Acosta, Ph.D.		
Date	August 12, 2005	Reg. No.	45,872

1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02767US1.

Dated: August 12, 2005

Respectfully submitted,

By 

Melissa W. Acosta, Ph.D.

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

Fulbright Tower

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Agent for Applicant



Docket No.: HO-P02767US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michael D. Schneider et al.

Application No.: 10/828,669

Confirmation No.: 6169

Filed: April 21, 2004

Art Unit: 1645

For: WNT AS A FACTOR FOR CARDIAC
MYOGENESIS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/828,669
				Filing Date	April 21, 2004
				First Named Inventor	Michael D. Schneider
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	HO-P02767US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-5,851,984	12-22-1998	Matthews et al.	
	AB*	US-6,159,462	12-12-2000	Matthews et al.	
	AC*	US-6,441,053	08-27-2002	Klein et al.	
	AD*	US-6,465,249	10-15-2002	Reya et al.	
	AE*	US-20020061514	05-23-2002	Underhill et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP-1222933	07-17-2002	Academisch Ziekenhuis		
	BB	WO-02/055109	07-18-2002	Academisch Ziekenhuis		
	BC	WO-02/057450	07-25-2002	Curagen Corporation		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Aberle et al., "β-catenin is a target for the ubiquitin-proteasome pathway," <i>The EMBO Journal</i> , 16(13): 3797-3804, 1997.	
	CB	Arias et al., "Wnt signalling: pathway or network?" <i>Curr. Opin. Gen. Dev.</i> , 9: 447-454, 1999.	
	CC	Chiu et al., "Cellular Cardiomyoplasty: Myocardial Regeneration With Satellite Cell Implantation," <i>Ann. Thorac. Surg.</i> , 60: 12-18, 1995.	
	CD	Frasch, "Induction of visceral and cardiac mesoderm by ectodermal Dpp in the early <i>Drosophila</i> embryo," <i>Nature</i> , 374: 464-467, 1995.	
	CE	Gray et al., "Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan," <i>Mol. Cell. Endocrin.</i> , 188: 253-260, 2002.	
	CF	Koh et al., "Stable Fetal Cardiomyocyte Grafts in the Hearts of Dystrophic Mice and Dogs," <i>J. Clin. Invest.</i> , 96: 2034-2042, 1995.	
	CG	Lee et al., "Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells," <i>Nature Biotech.</i> , 18: 675-678, 2000.	
	CH	Lee et al., "Wingless effects mesoderm patterning and ectoderm segmentation events via induction of its downstream target <i>sloppy paired</i> ," <i>Development</i> , 127: 5497-5508, 2000.	
	CI	Lewis et al., "Betaglycan binds inhibin and can mediate functional antagonism of activin signalling," <i>Nature</i> , 404: 411-414, 2000.	
	CJ	Li et al., "Autologous Porcine Heart Cell Transplantation Improved Heart Function After a Myocardial Infarction," <i>J. Throac. Cardiovasc. Surg.</i> , 119: 62-8, 2000.	
	CK	Li et al., "In Vivo Survival and Function of Transplanted Rat Cardiomyocytes," <i>Circ. Res.</i> , 78: 283-288, 1996.	
	CL	MacConell et al., "The Distribution of Betaglycan Protein and mRNA in Rat Brain, Pituitary,	
Examiner Signature			Date Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/828,669
				Filing Date	April 21, 2004
				First Named Inventor	Michael D. Schneider
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	HO-P02767US1

		and Gonads: Implications for a Role for Betaglycan in Inhibin-Mediated Reproductive Functions," <i>Endocrinology</i> , 143(3): 1066-1075, 2002.	
	CM	Miller et al., "Mechanism and function of signal transduction by the Wnt/ β -catenin and Wnt/ Ca^{2+} pathways," <i>Oncogene</i> , 18: 7860-7872, 1999.	
	CN	Miyoshi et al., "Activation of the β -Catenin Gene in Primary Hepatocellular Carcinomas by Somatic Alterations Involving Exon 31," <i>Cancer Res.</i> , 58: 2524-2527, 1998.	
	CO	Moon et al., "The Promise and Perils of Wnt Signaling Through β -Catenin," <i>Science</i> , 296: 1644-1646, 2002.	
	CP	Morin et al., "Activation of β -Catenin-Tcf Signaling in Colon Cancer by Mutations in β -Catenin or APC," <i>Science</i> , 275: 1787-1790, 1997.	
	CQ	Muller et al., "A β -catenin Mutation in a Sporadic Colorectal Tumor of the RER Phenotype and Absence of β -catenin Germline Mutations in FAP Patients," <i>Genes, Chromosomes & Cancer</i> , 22: 37-41, 1998.	
	CR	Nakamura et al., "A Wnt- and β -catenin-dependent pathway for mammalian cardiac myogenesis," <i>PNAS</i> , 100(10): 5834-5839, 2003.	
	CS	Palacios et al., "Mutations in the β -Catenin Gene (CTNNB1) in Endometrioid Ovarian Carcinomas," <i>Cancer Res.</i> , 58: 1344-1347, 1998.	
	CT	Park et al., "The Wingless Signaling Pathway Is Directly Involved in <i>Drosophila</i> Heart Development," <i>Developmental Biology</i> , 117: 104-116, 1996.	
	CU	Schneider et al., "Wnt antagonism initiates cardiogenesis in <i>Xenopus laevis</i> ," <i>Genes & Development</i> , 15: 304-315, 2001.	
	CV	Scorsin et al., "Can Grafted Cardiomyocytes Colonize Peri-Infarct Myocardial Areas?" <i>Circulation</i> , 94[suppl II]: II-337-II-340, 1996.	
	CW	Scorsin et al., "Surgery for Acquired Cardiovascular Disease: Comparison of the Effects of Fetal Cardiomyocyte and Skeletal Myoblast Transplantation on Postinfarction Left Ventricular Function," <i>J. Thorac. Cardiovasc. Surg.</i> , 119: 1169-75, 2000.	
	CX	Tavazzi, "Objectives of guidelines on heart failure," <i>Eur. Heart Journal</i> , 19(Suppl. L): L33-L35, 1998.	
	CY	Tomita et al., "Autologous Transplantation of Bone Marrow Cells Improves Damaged Heart Function," <i>Circulation</i> , 100(suppl. II): II-247-II-256, 1999.	
	CZ	Voeller et al., " β -Catenin Mutations in Human Prostate Cancer," <i>Cancer Res.</i> , 58: 2520-2523, 1998.	
	CA1	Wu et al., "Heart Development in <i>Drosophila</i> Requires the Segment Polarity Gene <i>wingless</i> ," <i>Developmental Biology</i> , 169: 619-628, 1995.	
	CB1	Zurawel et al., "Sporadic Medulloblastomas Contain Oncogenic β -Catenin Mutations," <i>Cancer Res.</i> , 58: 896-899, 1998.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Application No. (if known): 10/828,669

Attorney Docket No.: HO-P02767US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 671533049 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 12, 2005
Date

Signature

Pamela Tincha

Typed or printed name of person signing Certificate

Registration Number, if applicable

(713) 651-5151
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2 pages)
Information Disclosure Statement (2 pages)
Transmittal (1 page)